Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01680718 · ClinicalTrials.gov registry record · Early Phase 1
Neuropeptides and Social Behavior
A Early Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 160
- Enrollment target
NCT01680718 is a Early Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 160 participants.
The verdict
NCT01680718, a Early Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
It has long been established that interpersonal relationships can have a profound impact on health and well-being. Yet, we are still learning about the complex biological processes that contribute to positive social interactions and the ability to develop and maintain social relationships. Recent research has begun to focus on oxytocin and vasopressin, neuropeptides that are naturally produced in the hypothalamus, because administration of these neuropeptides has been associated with increased trust, generosity, empathy, cooperation, memory of social stimuli (e.g., faces), and brain activity in neural regions associated with social and emotional processes. To date, several aspects of oxytocin and vasopressin's effects on social behavior have been unexplored. As such, the overarching goal of this project is to examine the effects of intranasal oxytocin and vasopressin on social working memory, deception detection, sensitivity to interpersonal distance, empathy, and altruistic behavior. Understanding how oxytocin and vasopressin influence these aspects of social functioning will help to inform research that has begun to establish the potential for use of these neuropeptides in psychiatric disorders such as autism spectrum disorders and schizophrenia that are characterized by social deficits. For this study, we will recruit 150 healthy adults without a history of medical or psychiatric illness to come to the laboratory. In the first session, participants will complete several questionnaires. In the second session, participants will be randomly assigned to receive oxytocin, vasopressin, or placebo. The study nurses will measure temperature, heart rate, and blood pressure (female participants will also be asked to undergo a pregnancy test) before drug administration. Participants will then complete computer tasks. During the second session, we will also collect a saliva sample for genetic analysis and participants will be asked to complete several additional questionnair
Interventions
- DRUG Intranasal oxytocin
- DRUG Intranasal placebo
- DRUG Intranasal vasopressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01680718
The ClinicalTrials.gov registry entry for NCT01680718 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Intranasal oxytocin is the first listed.
NCT01680718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01680718 about?
NCT01680718 is a clinical study titled "Neuropeptides and Social Behavior". It has long been established that interpersonal relationships can have a profound impact on health and well-being. Yet, we are still learning about the complex biological processes that contribute to positive social interactions and the ability to develop and maintain social relationships. Recent re...
What is the current status of trial NCT01680718?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 160 participants. The study started on 2012-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01680718?
The interventions under investigation include: Intranasal oxytocin (DRUG), Intranasal placebo (DRUG), Intranasal vasopressin (DRUG).
Who is sponsoring clinical trial NCT01680718?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.